Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P17931 (galectin-3)
 2,860 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Activation of the mineralocorticoid receptor has been shown to be deleterious in cardiovascular diseases (CVDs). We have recently shown that lipocalin 2 (Lcn2), or neutrophil gelatinase-associated lipocalin (NGAL), is a primary target of aldosterone/mineralocorticoid receptor in the cardiovascular system. Lcn2 is a circulating protein, which binds matrix metalloproteinase 9 and modulates its stability. We hypothesized that Lcn2 could be a mediator of aldosterone/mineralocorticoid receptor profibrotic effects in the cardiovascular system. Correlations between aldosterone and profibrotic markers, such as procollagen type I N-terminal peptide, were investigated in healthy subjects and subjects with abdominal obesity. The implication of Lcn2 in the mineralocorticoid pathway was studied using Lcn2 knockout mice subjected to a nephrectomy/aldosterone/salt (NAS) challenge for 4 weeks. In human subjects, NGAL/matrix metalloproteinase 9 was positively correlated with plasma aldosterone and fibrosis biomarkers. In mice, loss of Lcn2 prevented the NAS-induced increase of plasma procollagen type I N-terminal peptide, as well as the increase of collagen fibers deposition and collagen I expression in the coronary vessels and the aorta. The lack of Lcn2 also blunted the NAS-induced increase in systolic blood pressure. Ex vivo, treatment of human fibroblasts with recombinant Lcn2 induced the expression of collagen I and the profibrotic galectin-3 and cardiotrophin-1 molecules. Our results showed that Lcn2 plays a key role in aldosterone/mineralocorticoid receptor-mediated vascular fibrosis. The clinical data indicate that this may translate in human patients. Lcn2 is, therefore, a new biotarget in cardiovascular fibrosis induced by mineralocorticoid activation.
...
PMID:Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. 2598 63

Objective of the study was to determine the correlation between plasma levels of galectin-3 and aldosterone and the dependence of their levels on different clinical characteristics in patients of young and middle age with stage 2 arterial hypertension. 160 male and female patients (80 persons of each gender) with stage 2 hypertension, regardless of the degree, and 27 relatively healthy persons were examined by determining the levels of galectin-3 and aldosterone in blood serum of the main and control groups of the examined persons. The absence of a statistically significant correlation (n=27, R=-0.28, p=0.16) between galectin-3 and aldosterone levels in generally healthy individuals was proved, and the presence of a direct correlation of the average strength between the level of neurohormones (n=160, R=0.64, p<0.0001) in patients of young and middle age with stage 2 hypertension was shown. In addition, the fact of fundamental differences in the nature of associations distribution with the similar level of galectin-3 and aldosterone was demonstrated: in patients with stage 2 and 3 AH as compared to patients with stage 1 AH; in patients with abdominal obesity as compared to patients with normal weight; in patients with dyslipidemia as compared to normal level of proatherogenic lipids. Positive correlation between association with a high level of galectin-3 and aldosterone with the presence of dyslipidemia (R=0.24, p=0.03), high degree of AH (R=0.30, p=0.01), an increase in the total number of risk factors (R=0.45, p<0.0001) and abdominal obesity (R=0.72, p<0.0001) was determined.
 ...
PMID:NATURE OF CORRELATIONS AND DEPENDENCE OF PLASMA CONCENTRATIONS OF GALECTIN-3 AND ALDOSTERONE ON DIFFERENT CLINICAL CHARACTERISTICS IN MALE AND FEMALE PATIENTS WITH ARTERIAL HYPERTENSION. 3201 Dec 99